Trial Profile
Multi Institutional Phase II Trial of Single Agent Regorafenib in Refractory Advanced Biliary Cancers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- 20 Sep 2021 Status changed from active, no longer recruiting to completed.
- 16 Jul 2021 Planned End Date changed from 1 Jun 2021 to 1 Jun 2022.
- 04 Nov 2020 Planned End Date changed from 1 Oct 2020 to 1 Jun 2021.